

# ForPatients

by Roche

Neovascular Age-related Macular Degeneration

## A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

**Trial Status**

Not Yet Recruiting

**Trial Runs In**

0 Countries

**Trial Identifier**

NCT06795048 2024-517545-13-00  
MR45638

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.

**Hoffmann-La Roche**

Sponsor

**Phase 4**

Phase

**NCT06795048 2024-517545-13-00 MR45638**

Trial Identifiers

### *Eligibility Criteria:*

**Gender**

All

**Age**

>=50 Years

**Healthy Volunteers**

No